Meet us at BIO Europe Spring 2021

Meet Sciomics at Bio Europe Spring - Focus: COVDI-19 Disease Severity Biomarkers

Corona | Sciomics is fully operational

Dear partners and friends,
We from Sciomics are hoping that you are all safe and well and would like to give you an update on our current activities in these challenging times.

To limit the spread of the COVID-19 virus and to ensure the safety of our employees as well as the continuation of all projects, Sciomics has early implemented preventive actions which have recently been further increased:
 
- only people critical to the laboratory activity are present on site
- implementation of non-overlapping teams for all on-site activities 
- efficient home office capabilities for all personnel

Through these actions, all our protein and post-translational analysis capabilities remain fully operational and we are able to continue all active projects as well as to begin new studies in the foreseeable future.  
Please feel free to contact us at any time if you have any questions or like to discuss how we may support you best during the current situation as well as in future projects.
 
As health is the highest good, we wish you all the best for you as well as your families and loved ones.

 

covid 19 operational v3 web

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

Testimonials

"The quality of the data we have obtained is exceptional."

 

Prof. Claudio Mauro
Birmingham University, Institute of Inflammation and Ageing, Birmingham, UK

"We have performed an acetylation array on primary T lymphocytes with Sciomics. The quality of the data we have obtained is exceptional. They have a model of collaboration with the team conducting the experiment. This means they generate the data and assist with further analyses of the data. The screening has opened up several exciting ways forward for us."

Product: scioAcetyl protein and protein acetylation profiling service (under co-development with selected partners)

 

Tweets